• Linarin Induces Cell Cycle Arrest and Senescence in NSCLC Ce

  2026-06-06

  This study identifies Linarin, a Herba Patriniae component, as a potent inhibitor of non-small-cell lung cancer (NSCLC) cell proliferation, acting through G0/G1 cell cycle arrest and induction of senescence. By integrating network pharmacology, in vitro assays, and molecular analysis, the research clarifies Linarin's mechanism—downregulation of key cell cycle regulators—highlighting its translational potential in NSCLC therapy.

• T0070907: Strategic Modulation of PPARγ in Inflammation & Di

  2026-06-05

  This thought-leadership article explores the mechanistic underpinnings and translational potential of T0070907, a nanomolar PPARγ antagonist. By contextualizing its role within the RXRα/PPARγ/NEDD4 axis and its implications for senescence-associated inflammation, adipogenesis, and cancer biology, we provide strategic guidance for translational researchers aiming to dissect and therapeutically target PPARγ signaling. Distinct from standard product pages, this article synthesizes recent literature, experimental protocols, and competitive insights to chart a roadmap for next-generation pathway intervention.

• N6-Methyl-dATP: Advancing DNA Replication Fidelity Studies

  2026-06-05

  N6-Methyl-dATP enables precise interrogation of DNA replication fidelity and methylation-driven genomic stability, offering unique leverage points for cancer epigenetics and antiviral research. This guide details applied workflows, troubleshooting strategies, and advanced applications, translating substrate innovation into reproducible molecular insights.

• DOTAP in Translational Gene Delivery: Mechanisms, Strategy,

  2026-06-04

  This article presents a thought-leadership perspective on 1,2-Dioleoyl-3-trimethylammonium-propane chloride (DOTAP) as a pivotal nucleic acid delivery vehicle. Blending mechanistic insight with strategic guidance, it contextualizes DOTAP within the evolving landscape of immunometabolic modulation, functional genomics, and next-generation therapeutics. Drawing on recent advances in immune-targeted nanodelivery and referencing both primary research and advanced application guides, the piece offers actionable recommendations for translational researchers seeking to optimize gene transfer protocols and bridge preclinical findings to clinical impact.

• Sulfo-NHS-LC-Biotin: Practical Guide for Surface Protein Bio

  2026-06-04

  Sulfo-NHS-LC-Biotin addresses the need for selective, permanent biotinylation of cell surface proteins in aqueous environments, bypassing the requirement for organic solvents. It should be employed for workflows involving extracellular protein labeling and is not appropriate for intracellular or reversible biotinylation applications due to its membrane impermeability and irreversible amide bond formation.

• IR-1061: Near Infrared Fluorescent Dye for Deep In Vivo Imag

  2026-06-03

  IR-1061 is a near infrared fluorescent dye with robust in vivo imaging performance in the NIR-II window. Its optimized molecular structure and solubility profile enable deep tissue visualization with minimal background. APExBIO provides IR-1061 with high purity and rigorous quality controls, supporting advanced biomedical research.

• Preserving Phosphorylation: Strategic Leverage for Translati

  2026-06-03

  Explore how precise inhibition of phosphatases underpins the fidelity of advanced signaling assays and translational discoveries. This article delivers mechanistic insight, validation evidence, and strategic guidance for deploying APExBIO’s Phosphatase Inhibitor Cocktail 2 (100X in ddH2O) in cutting-edge research—from metabolic genetics to proteostasis. Learn how securing protein phosphorylation integrity bridges evolutionary biology, disease modeling, and therapeutic innovation.

• β-Amanitin: Molecular Precision in Transcriptional Regulatio

  2026-06-02

  Explore the unique molecular precision of β-Amanitin as a research-grade inhibitor in transcriptional regulation studies. This deep-dive analyzes its mechanism, advanced assay implications, and how innovative detection platforms are changing the landscape of amatoxin research.

• L. gasseri ATCC33323 Maintains Gut Barrier via E-cadherin in

  2026-06-02

  Qian et al. (2024) elucidate how Lactobacillus gasseri ATCC33323 protects against DSS-induced colitis by preserving intestinal barrier integrity through NR1I3-mediated regulation of E-cadherin. These insights clarify probiotic mechanisms in inflammatory bowel disease and offer new directions for targeted microbiome-based therapies.

• PDK4-IN-1 Hydrochloride: Precision PDK4 Inhibition in Metabo

  2026-06-01

  PDK4-IN-1 hydrochloride offers nanomolar-selective inhibition of pyruvate dehydrogenase kinase 4, enabling high-fidelity modulation of mitochondrial energy metabolism in both in vitro and in vivo systems. Streamlined protocols, robust troubleshooting, and translational use-cases position it as a cornerstone for metabolic, cardiac, and tumor research.

• Nanozyme-Mediated Eradication of Intracellular Fn Potentiate

  2026-06-01

  This study introduces self-activatable polymeric nanozymes engineered to target and eliminate Fusobacterium nucleatum residing within tumor-associated macrophages in colorectal cancer. By reprogramming the macrophage immune environment and synergizing with CD47 blockade, the approach significantly enhances anti-tumor immunotherapy efficacy.

• BFH772 (VEGFR2 inhibitor): Technical Guidance for Angiogenes

  2026-05-31

  BFH772 is a highly selective VEGFR2 inhibitor developed for researchers requiring precise modulation of VEGFR2-mediated angiogenesis, particularly in tumor growth models. It is not suitable for protocols necessitating water solubility or broad-spectrum kinase inhibition, and requires careful handling due to its solubility and storage constraints.

• Enhanced ECL Substrate Detection: Bridging Protein Assays an

  2026-05-30

  Explore how the ECL Chemiluminescent Substrate Detection Kit (Enhanced) enables ultra-sensitive protein immunodetection and offers unique advantages for studies linking gut microbiota to cancer progression. This in-depth guide highlights pivotal mechanistic findings and practical assay optimization.

• T0070907: PPARγ Antagonist for Adipogenesis & Cancer Researc

  2026-05-29

  T0070907 empowers researchers to dissect PPARγ signaling with nanomolar selectivity, enabling reproducible inhibition of adipogenesis and precise cell cycle studies in cancer models. Its robust, covalent antagonism and compatibility with advanced pathway assays set a new standard for experimental clarity and troubleshooting in metabolic and oncology research.

• Dual-Action Kinase Inhibitors Accelerate p38α MAPK Dephospho

  2026-05-29

  This study demonstrates that certain kinase inhibitors, including Imatinib hydrochloride (STI571 hydrochloride), not only block kinase activity but also enhance dephosphorylation of p38α MAP kinase by stabilizing a phosphatase-accessible conformation. These findings reveal a new dual-action mechanism that may inform the design of more selective and potent kinase inhibitors for cancer and cell signaling research.

413 records 13/28 page Previous Next First page 上5页 1112131415 下5页 Last page